CN103403013B - 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物 - Google Patents

用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物 Download PDF

Info

Publication number
CN103403013B
CN103403013B CN201280010761.4A CN201280010761A CN103403013B CN 103403013 B CN103403013 B CN 103403013B CN 201280010761 A CN201280010761 A CN 201280010761A CN 103403013 B CN103403013 B CN 103403013B
Authority
CN
China
Prior art keywords
cancer
deoxyuridine
fluoro
cells
fdurd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280010761.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103403013A (zh
Inventor
克里斯托弗·麦圭根
扬·巴尔扎里尼
玛格达莱娜·斯卢萨尔塞克
布隆考·根齐
保拉·穆尔齐安妮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucana PLC
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45841523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103403013(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1103582.1A external-priority patent/GB201103582D0/en
Priority claimed from GBGB1105660.3A external-priority patent/GB201105660D0/en
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Priority to CN201510329656.2A priority Critical patent/CN104974206B/zh
Publication of CN103403013A publication Critical patent/CN103403013A/zh
Application granted granted Critical
Publication of CN103403013B publication Critical patent/CN103403013B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201280010761.4A 2011-03-01 2012-02-29 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物 Active CN103403013B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510329656.2A CN104974206B (zh) 2011-03-01 2012-02-29 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1103582.1A GB201103582D0 (enExample) 2011-03-01 2011-03-01
GB1103582.1 2011-03-01
GB1105660.3 2011-04-01
GBGB1105660.3A GB201105660D0 (en) 2011-04-01 2011-04-01 Chemical compounds
PCT/GB2012/050457 WO2012117246A1 (en) 2011-03-01 2012-02-29 Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510329656.2A Division CN104974206B (zh) 2011-03-01 2012-02-29 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物

Publications (2)

Publication Number Publication Date
CN103403013A CN103403013A (zh) 2013-11-20
CN103403013B true CN103403013B (zh) 2016-03-16

Family

ID=45841523

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280010761.4A Active CN103403013B (zh) 2011-03-01 2012-02-29 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
CN201510329656.2A Active CN104974206B (zh) 2011-03-01 2012-02-29 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510329656.2A Active CN104974206B (zh) 2011-03-01 2012-02-29 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物

Country Status (28)

Country Link
US (7) US8933053B2 (enExample)
EP (4) EP3447061B1 (enExample)
JP (1) JP5978232B2 (enExample)
KR (1) KR101885940B1 (enExample)
CN (2) CN103403013B (enExample)
AU (1) AU2012223012C1 (enExample)
BR (1) BR112013021986B1 (enExample)
CA (1) CA2828326C (enExample)
CL (1) CL2013002517A1 (enExample)
CY (2) CY1117445T1 (enExample)
DK (3) DK2681227T3 (enExample)
ES (4) ES2686219T3 (enExample)
HR (2) HRP20211967T1 (enExample)
HU (2) HUE029022T2 (enExample)
IL (1) IL228169A (enExample)
LT (1) LT3447061T (enExample)
MX (1) MX339822B (enExample)
NZ (1) NZ615270A (enExample)
PH (2) PH12013501723A1 (enExample)
PL (3) PL3031812T3 (enExample)
PT (2) PT3447061T (enExample)
RS (2) RS62721B1 (enExample)
RU (1) RU2614406C2 (enExample)
SG (1) SG192841A1 (enExample)
SI (2) SI3447061T1 (enExample)
SM (2) SMT202100715T1 (enExample)
WO (1) WO2012117246A1 (enExample)
ZA (2) ZA201306468B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974206A (zh) * 2011-03-01 2015-10-14 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2`-脱氧尿苷的氨基磷酸酯衍生物

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
JP2016506371A (ja) 2012-11-16 2016-03-03 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド ヌクレオシドプロドラッグを調製する方法
WO2015013352A2 (en) * 2013-07-25 2015-01-29 Patel Hasmukh B Nucleoside phosphoramidates and phosphoramidites
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
RU2553996C1 (ru) * 2013-11-27 2015-06-20 Андрей Александрович Иващенко Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
KR20170005492A (ko) * 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
SI3160978T1 (sl) 2014-06-25 2020-11-30 NuCana plc Gemcitabin predzdravila
PL225283B1 (pl) * 2014-07-24 2017-03-31 Univ Im Adama Mickiewicza W Poznaniu Pochodne 2,3’-anhydro-2’-deoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób wytwarzania i zastosowanie
US10570168B2 (en) 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
EP3303361A1 (en) * 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nucleotides for the treatment of cancer
WO2017087517A1 (en) * 2015-11-16 2017-05-26 Demeter Therapeutics, Llc Nucleic acid prodrugs
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3865136A1 (en) 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
MX2019005466A (es) 2016-11-13 2019-10-02 Imagine Pharma Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia.
CN109863160B (zh) 2016-12-23 2022-06-07 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
RU2644156C1 (ru) * 2017-02-28 2018-02-08 Александр Васильевич Иващенко Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
AU2017426847B2 (en) * 2017-08-08 2021-11-18 Sun Yat-Sen University Methods and compositions for treatment of multi-drug resistant tumors
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) * 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
US11597745B2 (en) * 2018-03-09 2023-03-07 Japan Science And Technology Agency β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction
CN110387226A (zh) * 2018-04-20 2019-10-29 天津大学 一种用于检测肿瘤的荧光探针及用途
US12221649B2 (en) 2018-11-30 2025-02-11 The University Of Tokyo Fluorescent probe for detecting carboxypeptidase activity
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
CN110840907B (zh) * 2019-08-16 2022-11-25 南京医科大学 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN116368143A (zh) * 2020-08-31 2023-06-30 埃莫里大学 5'-取代的单磷酸核苷、其前药及其相关用途
EP4630433A1 (en) 2022-12-07 2025-10-15 NuCana plc Synthesis of nucleoside derivative nuc-3373

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1291228A (zh) * 1998-01-23 2001-04-11 新生物生物公司 酶催化的治疗剂
US6455513B1 (en) * 1995-03-13 2002-09-24 University College Cardiff Consultants Ltd. Chemical compounds
WO2005012327A2 (en) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Nucleotide phosphoramidates as anticancer agents
CN101175763A (zh) * 2005-03-21 2008-05-07 卡迪夫大学学院顾问有限公司 用于治疗癌症的核苷化合物的氨基磷酸酯衍生物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US1002239A (en) 1902-04-11 1911-09-05 Stromberg Carlson Telephone Telephone system.
US2945038A (en) 1956-09-26 1960-07-12 Hoffmann La Roche 5-fluorocytosine and preparation thereof
US3201387A (en) 1963-09-18 1965-08-17 Heidelberger Charles 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
US3792039A (en) 1971-12-27 1974-02-12 Miles Lab Poly 2'-fluoro-2'-deoxyuridylic acid
DD279248A1 (de) 1989-01-01 1990-05-30 Akad Wissenschaften Ddr Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diamidophosphaten
RU2197964C2 (ru) * 1995-04-12 2003-02-10 Дзе Проктер Энд Гэмбл Компани Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
AU775601B2 (en) 1999-07-22 2004-08-05 Celmed Oncology (Usa) Inc. Enzyme catalyzed therapeutic activation
DE10109657A1 (de) 2001-02-28 2002-09-05 Menarini Ricerche Spa Verfahren zur Herstellung von (E)-5-(2-Bromvinyl)-2`-desoxyuridin
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
EP1827460A4 (en) 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
CN101922935B (zh) 2010-07-16 2012-07-18 北京大学 一种最小互易结构干涉型全光纤陀螺仪
PT2596004E (pt) 2010-07-19 2014-11-28 Gilead Sciences Inc Métodos para a preparação de pró-fármacos de fosforamidato diastereomericamente puros
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CN105061534A (zh) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
CA2828326C (en) * 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
HUE026338T2 (en) 2011-03-01 2016-05-30 Janssen Pharmaceutica Nv 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
BR112016025787B1 (pt) 2014-06-25 2022-12-13 NuCana plc Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma
US10570168B2 (en) 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
DK3197456T3 (en) 2015-05-14 2018-06-06 NuCana plc CANCER TREATMENTS
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455513B1 (en) * 1995-03-13 2002-09-24 University College Cardiff Consultants Ltd. Chemical compounds
CN1291228A (zh) * 1998-01-23 2001-04-11 新生物生物公司 酶催化的治疗剂
WO2005012327A2 (en) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Nucleotide phosphoramidates as anticancer agents
CN101175763A (zh) * 2005-03-21 2008-05-07 卡迪夫大学学院顾问有限公司 用于治疗癌症的核苷化合物的氨基磷酸酯衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
新型核苷类抗病毒药物的研究进展;刘琨等;《药学学报》;20061231;第41卷(第8期);第689-693页 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974206A (zh) * 2011-03-01 2015-10-14 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2`-脱氧尿苷的氨基磷酸酯衍生物
US11559542B2 (en) 2011-03-01 2023-01-24 NuCana plc Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer
US11925658B2 (en) 2011-03-01 2024-03-12 NuCana plc Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer

Also Published As

Publication number Publication date
CY1117445T1 (el) 2017-04-26
RS54776B1 (sr) 2016-10-31
BR112013021986A2 (pt) 2016-11-16
IL228169A (en) 2016-07-31
NZ615270A (en) 2015-09-25
US20160166596A1 (en) 2016-06-16
SMT201600132B (it) 2016-07-01
HUE060127T2 (hu) 2023-02-28
ZA201306468B (en) 2015-04-29
EP3447061A1 (en) 2019-02-27
ES3039965T3 (en) 2025-10-28
MX2013009815A (es) 2014-03-21
JP5978232B2 (ja) 2016-08-24
HRP20160346T1 (hr) 2016-05-06
SI3447061T1 (sl) 2022-02-28
AU2012223012B2 (en) 2015-06-18
PT3447061T (pt) 2021-12-23
SMT202100715T1 (it) 2022-01-10
ES2686219T3 (es) 2018-10-16
CN104974206B (zh) 2019-08-23
SG192841A1 (en) 2013-09-30
US20220023330A1 (en) 2022-01-27
US11925658B2 (en) 2024-03-12
EP4023299C0 (en) 2025-08-20
PL3447061T3 (pl) 2022-01-31
CN103403013A (zh) 2013-11-20
HK1192758A1 (zh) 2014-08-29
AU2012223012C1 (en) 2015-09-03
RU2614406C2 (ru) 2017-03-28
CA2828326C (en) 2019-05-07
EP3447061B1 (en) 2021-11-24
US20140057866A1 (en) 2014-02-27
US20170312302A1 (en) 2017-11-02
ES2569185T3 (es) 2016-05-09
US9655915B2 (en) 2017-05-23
ES2903097T3 (es) 2022-03-31
US11559542B2 (en) 2023-01-24
CA2828326A1 (en) 2012-09-07
US10022390B2 (en) 2018-07-17
MX339822B (es) 2016-06-13
EP2681227B1 (en) 2016-02-10
DK3447061T3 (da) 2022-01-03
EP4023299B1 (en) 2025-08-20
HRP20211967T1 (hr) 2022-03-18
PH12013501723A1 (en) 2013-10-07
US20230165886A1 (en) 2023-06-01
CN104974206A (zh) 2015-10-14
ZA201409013B (en) 2016-02-24
KR101885940B1 (ko) 2018-08-06
DK3031812T3 (en) 2018-09-17
JP2014506913A (ja) 2014-03-20
AU2012223012A1 (en) 2013-05-02
US8933053B2 (en) 2015-01-13
WO2012117246A1 (en) 2012-09-07
US20190201432A1 (en) 2019-07-04
BR112013021986B1 (pt) 2021-07-27
SI2681227T1 (sl) 2016-04-29
EP4023299A1 (en) 2022-07-06
LT3447061T (lt) 2022-01-25
PT3031812T (pt) 2018-10-18
HUE029022T2 (en) 2017-02-28
US10993957B2 (en) 2021-05-04
PH12015500485B1 (en) 2017-04-10
PH12015500485A1 (en) 2017-04-10
US20150183817A1 (en) 2015-07-02
EP3031812B1 (en) 2018-08-01
KR20140023913A (ko) 2014-02-27
US9221866B2 (en) 2015-12-29
EP3031812A1 (en) 2016-06-15
PL3031812T3 (pl) 2018-12-31
CY1124871T1 (el) 2022-11-25
RS62721B1 (sr) 2022-01-31
CL2013002517A1 (es) 2014-07-25
DK2681227T3 (da) 2016-02-22
EP2681227A1 (en) 2014-01-08
RU2013143862A (ru) 2015-04-10
PL2681227T3 (pl) 2016-08-31

Similar Documents

Publication Publication Date Title
CN103403013B (zh) 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
HK40069170A (en) Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
HK40001167A (en) Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
HK40001167B (en) Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
HK1192758B (en) Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: English note

Patentee after: NUCANA BIOMED Ltd.

Address before: British Airways

Patentee before: NuCana PLC